

Reference: FOI.ICB-2526/412

Subject: Tirzepatide Rollout in Primary and Specialist Care

I can confirm that the ICB does hold the information requested; please see responses below:

QUESTION	RESPONSE
<p>For the purposes of this request, I would be grateful if you could provide information as it applied to your ICB as structured in early 2025 (NHS Bristol, North Somerset and South Gloucestershire ICB). I am aware that some ICBs have since merged or reorganised. I would be grateful if you could answer the following questions:</p>	
<p>1. Is Tirzepatide available in primary care for weight management according to your ICB's formal position?</p>	<p>Yes</p>
<p>2. If yes, please provide the month/year for each of the following, where applicable:</p> <ul style="list-style-type: none"> i. Local pathway or ICB decision publication ii. Formal notification to primary care of rollout (e.g., via bulletin/guidance/communication) iii. Formulary inclusion/update to recommend primary care use iv. Local Enhanced Service (LES) or Local Commissioned Service (LCS) to support primary care prescribing 	<ul style="list-style-type: none"> i. June 2025 ii. June 2025 iii. June 2025 iv. June 2025
<p>3. Is Tirzepatide subject to an ICB-led prior approval process? If yes, please specify:</p>	<p>No</p>

<p>a) which clinicians or professionals are authorised to submit prior approval requests (e.g., GPs, specialists, pharmacists), and</p> <p>b) the month and year the process was introduced.</p>	
<p>4. Is Tirzepatide available for prescribing through specialist weight management services (e.g., Tier 3 or 4)?</p> <p>If yes, please provide the start date (month/year).</p>	<p>Yes, March 2025</p>
<p>5. Has the ICB provided any additional funding to specialist services to support the prescribing of Tirzepatide for weight management? If yes, please provide the start date (month/year).</p> <p>If available, please supply supporting documents such as:</p> <ul style="list-style-type: none"> i. your local primary care and/or secondary care weight management pathway, ii. any LCS/service specifications, iii. any communications, formulary updates or guidance issued to practices or specialist services about Tirzepatide prescribing. 	<p>Yes, March 2025</p> <p>Supporting documents for Tirzepatide available on the BNSSG Joint Formulary and BNSSG Remedy Referral website Home (Remedy BNSSG ICB)</p>

The information provided in this response is accurate as of 3 March 2026 and has been approved for release by Dr Joanne Medhurst, Chief Medical Officer for NHS Bristol, North Somerset and South Gloucestershire ICB.